ABSTRACT
The clinical presentation of COVID-19 varies from being asymptomatic to developing acute respiratory distress syndrome and multi-organ dysfunction. The diffuse microvascular thrombi in multiple organs seen in the autopsy of COVID-19 patients are similar to that of thrombotic microangiopathy (TMA). TMA is characterised by thrombus formation in the microvasculature with laboratory findings of microangiopathic haemolytic anaemia (MAHA) and thrombocytopenia. A 49-year-old male presented to the Aga Khan University Hospital, Karachi. with fever, diarrhoea, altered level of consciousness, and a positive nasopharyngeal swab for SARS-CoV-2. He developed severe thrombocytopenia, MAHA with 5.8% schistocytes, and worsening renal function on the sixth day of admission. Diagnosis of thrombotic thrombocytopenic purpura (TTP) was established based on PLASMIC score, and he was successfully treated with intravenous (IV) Methylprednisolone, therapeutic plasma exchange and IV Rituximab. The case emphasises the need to keep TTP in the differential diagnosis when a patient with COVID-19 develops severe thrombocytopenia, acute renal failure, or impaired level of consciousness, since prompt diagnosis and treatment is necessary to gain favourable outcome.
Subject(s)
COVID-19 , Epidermolysis Bullosa Acquisita , Kidney Failure, Chronic , Purpura, Thrombotic Thrombocytopenic , Male , Humans , Middle Aged , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/drug therapy , COVID-19/complications , SARS-CoV-2 , Purpura, Thrombotic Thrombocytopenic/complications , Purpura, Thrombotic Thrombocytopenic/diagnosis , Purpura, Thrombotic Thrombocytopenic/therapyABSTRACT
Identification of risk factors and sequelae of any given disease is of key importance. For common diseases, primary prevention and disease management are based on this knowledge. For orphan diseases, identification of risk factors and sequelae has been challenging. With the advent of large databases, e.g., TriNetX, this can now be addressed. We used TriNetX to identify risk factors and sequelae of epidermolysis bullosa acquisita (EBA), a severe and orphan autoimmune disease. To date, there is only enigmatic information on EBA comorbidity. We recruited 1,344 EBA patients in the Global Collaborative Network of TriNetX. Using the "explore outcomes" function we identified 55 diagnoses with a different prevalence between EBA and no-EBA patients. We next performed propensity-matched, retrospective cohort studies in which we determined the risk of EBA development following any of the identified 55 diseases. Here, 31/55 diseases were identified as risk factors for subsequent EBA. Importantly, the highest risk for EBA were other chronic inflammatory diseases (CID), especially lupus erythematosus and lichen planus. Lastly, we determined the risk to develop any of the identified diseases after EBA diagnosis. Here, 38/55 diseases were identified as sequelae. Notably, EBA patients showed an increased risk for metabolic and cardiovascular disease, and thrombosis. Furthermore, the risk for CIDs, especially lupus erythematosus and lichen planus, was elevated. These insights into risk factors and sequelae of EBA are not only of clinical relevance, e.g., optimizing cardiovascular disease risk, but in addition, point to shared pathogenetic pathways between EBA and other inflammatory diseases.
Subject(s)
Cardiovascular Diseases , Epidermolysis Bullosa Acquisita , Lichen Planus , Lupus Erythematosus, Systemic , Humans , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/epidemiology , Retrospective Studies , Cardiovascular Diseases/complications , Lupus Erythematosus, Systemic/diagnosis , Disease Progression , Risk FactorsABSTRACT
BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a rare auto-immune blistering disease. We report a case of Brunsting-Perry pemphigoid diagnosed by immunoelectron microscopy (IEM). PATIENTS AND METHODS: A 46-year-old man presented very pruriginous vesicles on the face and neck present for 6 years and which were difficult to diagnose and treat. The appearance of atrophic scars and milium cycts evoked EBA, which was confirmed at IEM. Due to limited involvement of the face and the neck, we conclude on EBA of the Brunsting-Perry pemphigoid variant. Treatment with dapsone produced a favorable outcome. DISCUSSION: Diagnosis of EBA is often difficult. In a case review, Asfour et al. collated 60 cases of Brunsting-Perry pemphigoid. These patients had either anti-collagen VII or anti-BP180 and anti-BP230 antibodies. IEM showed cleavage either under the lamina densa or within the lamina lucida, suggesting that Brunsting-Perry pemphigoid is a subtype of EBA or bullous pemphigoid (BP), depending on the paraclinical elements, and localized to the head and neck. The majority of EBA-like cases required systemic therapy, whereas in the presence of BP antibodies, topical corticosteroids were effective. CONCLUSION: We report a case of EBA of the Brunsting-Perry pemphigoid type, diagnosed by IEM after 6 years of progression. We highlight the diagnostic and nosological difficulties of Brunsting-Perry pemphigoid. Classification of this dermatosis as a subtype of EBA or BP may enable effective adaptation of therapeutic management, which has not as yet been coded.
Subject(s)
Epidermolysis Bullosa Acquisita , Pemphigoid, Bullous , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/drug therapy , Humans , Male , Middle Aged , Pemphigoid, Bullous/classification , Pemphigoid, Bullous/complications , Pemphigoid, Bullous/diagnosis , Pemphigoid, Bullous/drug therapyABSTRACT
BACKGROUND Epidermolysis bullosa acquisita is a rare, subepithelial bullous disorder, which is distinguished from other autoimmune blistering diseases by the production of antibodies against type VII collagen. CASE REPORT Here, we describe the case of a 79-year-old male resident of the Northern Mariana Islands who presented to the clinic with multiple blistering skin lesions. CONCLUSIONS The primary focus of treatment is to prevent disease progression and serious complications of scarring (including blindness and respiratory obstruction) by avoiding physical trauma and suppressing the immune systems with agents, including corticosteroids, colchicine, dapsone, methotrexate, and cyclophosphamide. Successful treatment of the condition should involve a multidisciplinary team of medical professionals with regular monthly follow-ups during periods of active disease.
Subject(s)
Autoimmune Diseases/diagnosis , Epidermolysis Bullosa Acquisita/diagnosis , Abscess/therapy , Aged , Anti-Inflammatory Agents/therapeutic use , Autoimmune Diseases/drug therapy , Collagen Type VII/immunology , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/drug therapy , Humans , Male , Micronesia , Prednisone/therapeutic use , Staphylococcal Infections/therapyABSTRACT
BACKGROUND/AIMS: To describe the ocular manifestations associated with epidermolysis bullosa acquisita (EBA). METHODS: This retrospective study was conducted at a tertiary bullous disease clinic. Consecutive patients were enrolled with biopsy proven diagnosis of EBA, with ocular involvement and a follow-up of at least 36 months. A multidisciplinary team of dermatologists, ENT specialists and ophthalmologists evaluated all patients. Immunological workup included direct (including immune-electron microscopy) and indirect immunofluorescence. Ophthalmological examination included best-corrected visual acuity (BCVA) and slit-lamp examination with grading of conjunctival fibrosis using the Tauber classification. RESULTS: Nine patients (five females, four males) were included. The mean age at diagnosis was 32 years (range 1-52 years). Follow-up ranged from 3 to 18 years (mean 10.7 years). Conjunctival fibrosis was present in all affected eyes and was stage III or greater in 60% of patients. Eight patients (14 eyes) had corneal involvement most frequently associated with trichiasis-associated mechanical irritation or extensive cicatrising conjunctivitis. Corneal lesions developed on three eyes of three patients without eyelid disease or severe fibrosis or any identifiable triggering factor. Eyelids were affected in six patients, with trichiasis being the most common feature (affecting three patients, four eyes). Corneal-related blindness occurred in at least one eye in 44% of the patients. CONCLUSION: EBA may be associated with devastating ocular manifestations. Most patients develop severe cicatrising conjunctivitis. A subset of patients may present with isolated corneal lesions. Further studies are warranted to assess the effects of systemic treatments on the evolution of ocular manifestations.
Subject(s)
Conjunctiva/pathology , Cornea/pathology , Epidermolysis Bullosa Acquisita/pathology , Eyelids/pathology , Adolescent , Adult , Blindness/etiology , Child , Child, Preschool , Epidermolysis Bullosa Acquisita/complications , Female , Follow-Up Studies , Humans , Infant , Male , Middle Aged , Retrospective Studies , Visual Acuity , Young AdultSubject(s)
Airway Obstruction/therapy , Epidermolysis Bullosa Acquisita/therapy , Immunoglobulins, Intravenous/therapeutic use , Laryngeal Diseases/therapy , Pharyngeal Diseases/therapy , Airway Obstruction/complications , Epidermolysis Bullosa Acquisita/complications , Humans , Laryngeal Diseases/complications , Male , Middle Aged , Pharyngeal Diseases/complications , Treatment OutcomeSubject(s)
Antineoplastic Agents/administration & dosage , Epidermolysis Bullosa Acquisita , Lymphoma, Mantle-Cell , Skin/pathology , Triamcinolone/administration & dosage , Biopsy/methods , Diagnosis, Differential , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/pathology , Epidermolysis Bullosa Acquisita/therapy , Glucocorticoids , Humans , Injections, Intralesional , Lymphoma, Mantle-Cell/complications , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/pathology , Male , Middle Aged , Treatment OutcomeABSTRACT
A 49-year-old man with recalcitrant mechanobullous epidermolysis bullosa acquisita (EBA) with significant esophageal involvement was treated with rituximab. EBA is a chronic autoimmune subepidermal bullous disease. It is characterized by skin fragility and scarring caused by circulating and tissue bound antibodies to type VII collagen. EBA is often unresponsive or poorly responsive to conventional immunosuppressive therapies such as corticosteroids, methotrexate, and cyclosporine. The burden of long-term use of immunosuppressants also limits their use in the treatment of chronic autoimmune diseases such as EBA. Since a validated and objective way of measuring disease activity in patients with EBA has not been described, we used the Epidermolysis Bullosa Disease Activity Scoring Index (EBDASI), for hereditary EB, as a surrogate to measure disease severity and activity in our patient with EBA. After three courses of rituximab over three years, our patient has achieved near complete clinical remission from disease activity. The patient's response suggests that treatment with rituximab may be a valuable treatment regimen for severe mechanobullous EBA, which is demonstrated by paralleled declines in objective disease activity scores, the EBDASI. This is in line with recently observed beneficial effects of rituximab in the management of EBA.
Subject(s)
Epidermolysis Bullosa Acquisita/drug therapy , Esophageal Diseases/drug therapy , Immunologic Factors/therapeutic use , Rituximab/therapeutic use , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/pathology , Esophageal Diseases/etiology , Esophageal Diseases/pathology , Humans , Male , Middle AgedABSTRACT
Orf is a DNA parapoxvirus transmitted to humans by contact with infected goats and sheep. Many complications have been reported after orf infection, including erythema multiforme. A few cases of autoimmune bullous dermatosis complicating orf disease have been reported to date. They are usually characterized by tense blister eruptions with or without mucosal involvement; linear deposition of C3, IgG and/or IgA along the basement membrane; and negativity of indirect immunofluorescence analysis and enzyme-linked immunosorbent assay (ELISA) (performed in four of 11 reported cases). These analyses have targeted antigens of bullous pemphigoid, mucous membrane pemphigoid or epidermolysis bullosa acquisita, except one case of mucosal pemphigoid with antilaminin-332 antibodies. We describe the case of a patient who presented with an ulceration on his finger 10 days after direct contact with a lamb during Eid al-Adha. Four weeks later he developed a severe tense blistering eruption associated with mucous membrane erosions. Indirect immunofluorescence analysis using the patient's serum revealed circulating antibasement membrane IgG that bound the dermal side of salt-split skin. ELISA was positive for recombinant immunodominant NC1 domain of type VII collagen. We finally diagnosed epidermolysis bullosa acquisita complicating probable human orf infection.
Subject(s)
Ecthyma, Contagious/complications , Epidermolysis Bullosa Acquisita/complications , Adult , Animals , Fingers , Food Handling , Humans , Islam , Male , SheepABSTRACT
Epidermolysis bullosa acquisita is a severe autoimmune subepidermal bullous disease. In this report, we described for the first time a patient with epidermolysis bullosa acquisita who developed acute renal failure. There is a possibility that epidermolysis bullosa acquisita and acute renal failure's pathogenesis shared some common autoimmune pathways. Moreover, acute blood volume reduction may be another cause of prerenal kidney failure. Further studies are needed to verify our hypothesis.
Subject(s)
Acute Kidney Injury/etiology , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/pathology , Acute Kidney Injury/drug therapy , Aged , Biopsy , Epidermolysis Bullosa Acquisita/drug therapy , Fluorescent Antibody Technique, Direct , Humans , Male , Skin/pathology , Treatment OutcomeABSTRACT
We report the first case of a liver transplant in a patient with epidermolysis bullosa acquisita and associated hepatitis B virus-hepatitis D virus cirrhosis and its inherent technical issues. Epidermolysis bullosa acquisita is an autoimmune multisystem disorder involving skin and mucosa characterized by the appearing of blisters and erosions. The more severe forms may result in nutritional compromise, anemia, osteopenia, dilated cardiomyopathy, laryngeal mucosal involvement, esophageal strictures, bladder, and kidney involvement requiring surgical intervention. Epidermolysis bullosa acquisita has become recognized as a multisystem disorder that poses several surgical challenges. This case shows that liver transplant is a feasible procedure in patients affected by epidermolysis bullosa acquisita. Patients with epidermolysis bullosa acquisita require a particular pretransplant assessment and a dedicated intra- and postoperative management of every invasive procedure that can traumatize the skin and mucosal epithelium to achieve an uneventful liver transplant. Epidermolysis bullosa acquisita does not represent a contraindication to liver transplant, and immunosuppression after transplant may favor a good systemic control of this immunologic disorder.
Subject(s)
End Stage Liver Disease/surgery , Epidermolysis Bullosa Acquisita/complications , Hepatitis B/complications , Hepatitis D/complications , Liver Transplantation , End Stage Liver Disease/diagnosis , End Stage Liver Disease/immunology , End Stage Liver Disease/virology , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/immunology , Female , Hepatitis B/diagnosis , Hepatitis B/immunology , Hepatitis B/virology , Hepatitis D/diagnosis , Hepatitis D/immunology , Hepatitis D/virology , Humans , Immunosuppressive Agents/therapeutic use , Liver Transplantation/adverse effects , Middle Aged , Risk Factors , Treatment OutcomeABSTRACT
Epidermolysis bullosa acquisita (EBA) is a rare chronic subepidermal bullous autoimmune disease. The occurrence of acquired hemophilia A (AHA) is low and so the coexistence of EBA and AHA is extremely rare. We herein described a case of EBA coexisting with AHA and a case of EBA coexisting with AHA and hepatitis B. These EBA may be related to the pathogenesis of AHA. In this study, we analyzed the clinical features in the two Chinese cases of EBA coexisting with AHA, and found esophageal hemorrhage and hematemesis were the main symptoms of both patients. Cyclosporin, prednisone and lamivudine effectively control EBA with AHA and hepatitis B. The dose of cyclosporin should be more than 4 mg/kg per day and the period of treatment should be longer than 5 months to reduce the risk of EBA co-occurring with AHA.
Subject(s)
Autoimmune Diseases/complications , Epidermolysis Bullosa Acquisita/complications , Esophageal Diseases/etiology , Gastrointestinal Hemorrhage/etiology , Hematemesis/etiology , Hemophilia A/complications , Hepatitis B/complications , Adult , Autoantibodies/analysis , Autoimmune Diseases/blood , Autoimmune Diseases/drug therapy , Autoimmune Diseases/pathology , Biopsy , China , Collagen Type VII/immunology , Cyclosporine/administration & dosage , Cyclosporine/therapeutic use , Epidermolysis Bullosa Acquisita/blood , Epidermolysis Bullosa Acquisita/drug therapy , Epidermolysis Bullosa Acquisita/pathology , Factor VIII/immunology , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Hemophilia A/blood , Hemophilia A/drug therapy , Hepatitis B/blood , Hepatitis B/drug therapy , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Lamivudine/administration & dosage , Lamivudine/therapeutic use , Male , Middle Aged , Prednisone/administration & dosage , Prednisone/therapeutic use , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/therapeutic use , Skin/pathologyABSTRACT
Abstract: Epidermolysis bullosa acquisita is a severe autoimmune subepidermal bullous disease. In this report, we described for the first time a patient with epidermolysis bullosa acquisita who developed acute renal failure. There is a possibility that epidermolysis bullosa acquisita and acute renal failure's pathogenesis shared some common autoimmune pathways. Moreover, acute blood volume reduction may be another cause of prerenal kidney failure. Further studies are needed to verify our hypothesis.
Subject(s)
Humans , Male , Aged , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/pathology , Acute Kidney Injury/etiology , Skin/pathology , Biopsy , Epidermolysis Bullosa Acquisita/drug therapy , Treatment Outcome , Fluorescent Antibody Technique, Direct , Acute Kidney Injury/drug therapySubject(s)
Deglutition Disorders/complications , Deglutition Disorders/diagnosis , Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/diagnosis , Esophagus/pathology , Constriction, Pathologic/complications , Constriction, Pathologic/diagnosis , Humans , Male , Middle AgedSubject(s)
Autoimmune Diseases/complications , Epidermolysis Bullosa Acquisita/complications , Facial Dermatoses/complications , Skin Diseases, Vesiculobullous/complications , Aged , Autoimmune Diseases/drug therapy , Autoimmune Diseases/pathology , Blister/complications , Blister/drug therapy , Blister/pathology , Cyclosporine/therapeutic use , Dermatologic Agents/therapeutic use , Epidermolysis Bullosa Acquisita/drug therapy , Epidermolysis Bullosa Acquisita/pathology , Facial Dermatoses/drug therapy , Facial Dermatoses/pathology , Female , Humans , Pemphigoid, Bullous/complications , Pemphigoid, Bullous/drug therapy , Pemphigoid, Bullous/pathology , Skin Diseases, Vesiculobullous/drug therapy , Skin Diseases, Vesiculobullous/pathologySubject(s)
Epidermolysis Bullosa Acquisita/complications , Epidermolysis Bullosa Acquisita/pathology , Psoriasis/complications , Betamethasone/therapeutic use , Biopsy, Needle , Colchicine/administration & dosage , Drug Therapy, Combination , Epidermolysis Bullosa Acquisita/drug therapy , Follow-Up Studies , Humans , Immunohistochemistry , Male , Middle Aged , Minocycline/therapeutic use , Psoriasis/drug therapy , Psoriasis/pathology , Rare Diseases , Recurrence , Risk Assessment , Treatment OutcomeABSTRACT
PURPOSE: Epidermolysis bullosa acquisita (EBA) is a very rare disease of a chronic autoimmune subepidermal blistering, usually manifesting as skin fragility, blisters and erosions. In this article, we report a successful THA in a patient with osteonecrosis of the femoral head with EBA and methicillin-resistant staphylococcus aureus (MRSA) skin carriage. METHODS: A 59-year-old woman had severe and debilitating left hip pain due to osteonecrosis of the femoral head. She had suffered from EBA for the past 7 years. She had received several courses of intravenous steroid pulse therapy in the past, and taking 6 mg of prednisone and 100 mg of minocycline per day for infected skin blisters. Severe blisters and scars covered her body, especially at the prone area. A bacteriological examination taken using a cotton-swab returned MRSA at the nasal cavity and anterolateral part of the proximal femur. RESULTS: We employed an antibiotic prophylactic protocol used for one-stage revision for infected hip prosthesis. Primary THA was performed using the anterior approach with antibiotic-loaded cement, and the skin was fully covered with a soft and conformable foam dressing.1-year post-op, there are no signs of infection. The Harris Hip Score improved from 37 pre-op to 93.4 at 1 year post-op. CONCLUSIONS: Although care must be taken by medical professionals to avoid the prescription of unnecessary antibiotics, when used appropriately, there appears to be substantial benefits to be gained in the field of joint replacement for patients who are at high risk of infection.